虽然这些产品在RNAi技术的害虫控制方面代表了重大进步,但在开发方面仍有很长的路要走,特别是对于外源应用。然而,观察到对这些应用的开发越来越重视(图4)。然而,大多数研究的基础研究水平在中到低范围,表明需要进一步优化以推进产品开发的市场成熟。
RNA interference (RNAi) is a naturally occurring biological pathway in which small, double-stranded RNA molecules suppress gene expression in an exquisitely sequence-specific manner Exogenous ...
Atalanta Therapeutics has technology that delivers RNA interference (RNAi) therapies into the CNS. The startup has spent the past four years quietly working on its technology and potential drugs.
1 天
来自MSNWheat crops are dying, and scientists just found out why — here's what it means for our ..."This could be a game-changer for controlling these serious pathogens." Wheat crops are dying, and scientists just found out ...
Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.
[28] RNA interference (RNAi) is a naturally occurring biological pathway in which small, double-stranded RNA molecules suppress gene expression in an exquisitely sequence-specific manner Exogenous ...
WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new ...
Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...
7 天on MSN
A high-quality genome assembly of Silene latifolia was generated by researchers at CNRS/Université Claude Bernard Lyon 1 and ...
The global RNA based therapeutic market size is calculated at USD 9.46 billion in 2025 and is expected to reach around USD 40 ...
On March 18 th Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec will be giving an oral presentation in the first session dedicated to OPMD at the 2025 Muscular ...
CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $83.8 million in its fourth quarter. On a per-share basis, the Cambridge, ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果